GENELUX Corp (GNLX)
Genelux develops cancer immunotherapies based on a modified vaccinia virus that infects and destroys tumor cells. It last closed at $2.00 on Nov 17, up 4.17% on the day.
Key Stats
Fiscal 2025Not reported for this period.
From GNLX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 16).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on GNLX in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $2.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Roth MKM | Initiated | Buy | $10 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 32% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the 20 day average at $1.98, and the nearest resistance the Pivot R1 at $2.07.
| RSI (14) | 45.82 | Middle of its range | Neutral |
| MACD | -0.11 | Above its signal line | Bullish |
| Stochastic | 31.0 | Middle of its range | Neutral |
| ADX (14) | 14.7 | No clear trend | |
| Williams %R | -54.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -34.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.2% | Change over 10 sessions | Bullish |
| ATR (14) | $0.17 | Typical daily range, 8.4% of price |
| RSI (14) | 35.17 | Weak, oversold below 30 | Neutral |
| MACD | -0.26 | Below its signal line | Bearish |
| Stochastic | 13.7 | Near the bottom of its range | Oversold |
| ADX (14) | 22.0 | Weak trend | |
| Williams %R | -80.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -143.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −19.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.36 | Typical daily range, 17.8% of price |
What happened before
See how GNLX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GNLX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in GNLX in the last 90 days.
GNLX Institutional Ownership
Full report →- ▲30 buying vs 22 selling
- ▲Held by funds +0.9 pts
- ▲Funds holding +6
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 78 | 72 | +8.3% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 21.3% | 20.4% | +0.9 pts |
| New / increased | 14 / 16 | 10 / 18 | +7.1% |
| Reduced / sold out | 14 / 8 | 15 / 10 | −12.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GNLX is in one of them and how their past GNLX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GNLX in an article yet. Here's the latest on the wider market.
About GENELUX
Genelux is a biopharmaceutical company based in Westlake Village, California, that develops cancer treatments built on a modified vaccinia virus. Its lead candidate, Olvi-Vec, is designed to infect and destroy tumor cells while prompting the immune system to attack cancer throughout the body. The company is testing it in ovarian cancer, lung cancer and small cell lung cancer, aiming at patients whose tumors have responded poorly to standard treatments such as chemotherapy. It also operates a manufacturing facility in San Diego and has licensed rights to Olvi-Vec in China to a partner.
- Headquarters
- Westlake Village, CA



